Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.

Proceedings of the National Academy of Sciences of the United States of America - 13 Jul 2010

Lutterbuese Ralf, Raum Tobias, Kischel Roman, Hoffmann Patrick, Mangold Susanne, Rattel Benno, Friedrich Matthias, Thomas Oliver, Lorenczewski Grit, Rau Doris, Schaller Evelyne, Herrmann Ines, Wolf Andreas, Urbig Thomas, Baeuerle Patrick A, Kufer Peter

Abstract excerpt

Epidermal growth factor receptor (EGFR)-specific monoclonal antibodies predominantly inhibit colorectal cancer (CRC) growth by interfering with receptor signaling. Recent analyses have shown that patients with CRC with mutated KRAS and BRAF oncogenes do not profit from treatment with such antibodies. Here we have used the binding domains of cetuximab and pantitumumab for constructing T cell-engaging BiTE...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Colorectal Neoplasms

Share to ErbB Receptors

Share to Genes, ras

Share to Neoplasms

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 20616015
DOI: 10.1073/pnas.1000976107
PMCID: PMC2906601

Genes

EGFR
BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.PMID 20616015Read ↗

CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.Semantic proximity Read ↗

A Simplified Function-First Method for the Discovery and Optimization of Bispecific Immune Engaging AntibodiesSemantic proximity Read ↗

Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.Semantic proximity Read ↗

Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager.Semantic proximity Read ↗

Targeting human γδ T cells as a potent and safe alternative to pan-T cells bispecific cell engagersSemantic proximity Read ↗

Bispecific antibodies for immune cell retargeting against cancerSemantic proximity Read ↗

Chemically Programmable and Switchable CAR‐T TherapySemantic proximity Read ↗

Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy.Semantic proximity Read ↗

Generation of dual specific bivalent BiTEs (dbBIspecific T-cell Engaging antibodies) for cellular immunotherapySemantic proximity Read ↗

Single injection of modified self-amplifying RNA encoding a CD19 bispecific T cell engager mediates long-term malignant B cell clearanceSemantic proximity Read ↗

A Broad-Based Characterization of a Cell-Penetrating, Single Domain Camelid Bi-Specific Antibody Monomer That Targets STAT3 and KRAS Dependent Cancers.Semantic proximity Read ↗

Synergistic Approach of Antibody-Photosensitizer Conjugate Independent of KRAS-Mutation and Its Downstream Blockade Pathway in Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.